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Response to Letter by Proctor
and Tamborello
Response
It is premature to comment on SAINT II before any manu-
script is published. However, the suggestion that different prod-
ucts were used for the 2 SAINT trials can be discounted.
Relevant knowledge contained in the patent application was
applied identically to the study drug supplied for SAINT I and
II. The patent application for test article preparation was filed
in Sweden in May 2000 and filed internationally in May 2001.
SAINT I commenced in April 2003. The suggestion that the
SAINT I trial may have been delayed pending animal toxicity
tests is also untrue. Appropriate testing was completed before
early phase trials. The SAINT I protocol was finalized in
December 2002, after the last of the preclinical efficacy studies
advised by STAIR guidelines had concluded.1,2 Recruitment to
SAINT I started promptly after Institutional Review Board and
regulatory approvals, in April 2003, and completed ahead of
schedule.3,4 Recruitment into SAINT II was impaired for a while
in the US because of an interim restriction on the protocol
barring concomitant treatment with rt-PA pending completion of
the FDA requested interaction data.
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